about
GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.Recommendations on the use of everolimus in lung transplantation.Biomarkers of pulmonary rejection.Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital.Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem.Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety.Lung transplantation in systemic sclerosis: A single center cohort study.Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.Tuberculosis in lung transplant recipients.Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients.10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation.Prevalence and Diagnosis of Chronic Kidney Disease in Maintenance Lung Transplant Patients: ICEBERG Study.Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation.Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation.[Lung transplantation in pulmonary fibrosis and other interstitial lung diseases].Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans.Characteristics of candidates for lung transplantation due to chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency emphysema.Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients.A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary.Acute and chronic pleural complications in lung transplantation.Restrictive allograft syndrome and idiopathic pleuroparenchymal fibroelastosis: do they really have the same histology?BALF cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients.Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study.Epidemiology and Risk Factors for Cancer After Lung Transplantation.High intra-individual variability of cyclosporine pharmacokinetics in lung transplant recipients without cystic fibrosisSuccessful pregnancy in a patient with pulmonary hypertension associated with mixed collagen vascular disease[Long-term outcomes of treatment with bosentan in pulmonary hypertension]Donor-to-host transmission of bacterial and fungal infections in lung transplantationBlood cyclosporine C0 and C2 concentrations and cytomegalovirus infections following lung transplantationCoronary angiography in patients undergoing evaluation for lung transplantationPrevención de la enfermedad por citomegalovirus en el trasplante de pulmón[Combination therapy for pulmonary arterial hypertension]
P50
Q37934102-3EE7B6B5-CAB4-4FB5-8CFC-2034C1CF575EQ38070460-AB1876E4-CF21-48B5-BDC4-7D4B1AC6E4A8Q38158569-8F3585B2-A5A6-46B5-A96A-90C26F19BEB5Q38280283-4BF86700-EF34-4062-A155-187CF88DF39AQ38312424-27E5C76D-31EB-448A-A866-74F0C89A9334Q38822159-B62C9479-BF87-4891-9503-458736A0E9ACQ40004415-8C66C278-2483-4520-B1B7-2078632503FFQ40251508-4A2E9229-37CA-4EAE-8B12-3715AE1533A9Q40293836-C16602C5-DBD9-4891-9C44-27530C7CDDB0Q40514822-842B7AE2-7A8C-407D-88A6-A574A99CAD58Q40867351-82F51E6A-D0ED-492F-AD38-70DBF4E9A766Q41015559-78915220-BDB6-40EC-BD07-7AFBCC0A9D0EQ41465843-79D15480-B036-4178-BE5A-65CABECA4DCAQ43198622-352AA86A-739B-4693-91AA-2E47DB7A5B6CQ43442056-82A06352-AC47-42E0-BCD4-2E26DBE7055BQ43963002-72328EFF-FF82-4CBB-A431-3BB2A005177BQ43963087-90B43D9B-CAF5-49FF-A747-F827EEFB4B44Q44454561-DDDC4707-7D2F-4D71-8D01-508743751896Q44469255-6744C3EE-CF37-49D2-A202-6831731A922BQ46062495-96369A81-EA79-49B5-9F47-E04B54AAA377Q46600097-B94DA425-B0E4-4EF1-BFCC-57D2EDFC8428Q47415807-E3AF4708-E13C-4DE6-91F8-876F8257E644Q47990359-54248BC4-B84A-46B5-9F1C-568B69472695Q48122419-8D1DF337-3096-4994-82A2-B4A5182EBDC5Q48249771-C35F65BC-CE67-422E-A632-BBE08931D7A2Q49338702-5210C8D1-826C-4EBD-B24D-9B376A3F5BD1Q57212294-A5D0CE98-61F8-4EFC-8CBE-C2F7354AAB47Q57212461-F1F8F3FC-ABC2-4730-9F3B-589A76AA3F18Q57216964-3A2B81D5-8BE5-4C02-A93C-5CF7A7DF0D24Q57217456-5F95AEFC-D839-423E-99A7-B1E6155D3013Q57218408-077D356C-9682-43DF-832D-7D878D6C6C00Q57218985-ADADF334-94CD-4EAF-BEF2-2885BF9781D2Q58854030-238AB0DC-65DE-4798-9AF7-7D211770B56EQ83279783-72BE1456-A528-40CA-983C-6EE8B597FE25
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Víctor Monforte
@ast
Víctor Monforte
@en
Víctor Monforte
@es
Víctor Monforte
@nl
type
label
Víctor Monforte
@ast
Víctor Monforte
@en
Víctor Monforte
@es
Víctor Monforte
@nl
prefLabel
Víctor Monforte
@ast
Víctor Monforte
@en
Víctor Monforte
@es
Víctor Monforte
@nl
P106
P1153
26027564600
57195496301
P21
P31
P496
0000-0002-2918-7679